Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Antiangiogenic therapy in malignant gliomas

Norden, Andrew Da,b,c; Drappatz, Jana,b,c; Wen, Patrick Ya,b,c

doi: 10.1097/CCO.0b013e32831186ba
Brain and nervous system: Edited by Marc Sanson
Buy

Purpose of review Antiangiogenic drugs are increasingly used in malignant glioma therapy. This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy.

Recent findings Combination therapy with bevacizumab, the humanized monoclonal antibody against vascular endothelial growth factor, and irinotecan has emerged as the treatment of choice for recurrent malignant gliomas, prolonging progression-free survival markedly in comparison with historical controls. Several small molecule tyrosine kinase inhibitors of the vascular endothelial growth factor receptor are under investigation and show promise as well.

Summary Antiangiogenic treatments are effective and well tolerated options for recurrent malignant glioma. Future studies will determine whether these drugs have a role in first line therapy. Studies are in progress to elucidate mechanisms of resistance and suggest approaches to further improve survival in patients with these challenging tumors.

aDivision of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, USA

bCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, USA

cHarvard Medical School, Boston, Massachusetts, USA

Correspondence to Andrew D. Norden, Center for Neuro-Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA Tel: +1 617 632 2166; fax: +1 617 632 4773; e-mail: anorden@partners.org

© 2008 Lippincott Williams & Wilkins, Inc.